Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Effect of chromoendoscopy in the proximal colon on colorectal neoplasia detection in Lynch syndrome: a multicenter randomized controlled trial.

Haanstra JF, Dekker E, Cats A, Nagengast FM, Hardwick JC, Vanhoutvin SA, de Vos Tot Nederveen Cappel WH, Vasen HF, Kleibeuker JH, Koornstra JJ.

Gastrointest Endosc. 2019 Apr 24. pii: S0016-5107(19)31650-5. doi: 10.1016/j.gie.2019.04.227. [Epub ahead of print]

PMID:
31028782
2.

Reasons why the diagnosis of serrated polyposis syndrome is missed.

van Herwaarden YJ, Pape S, Vink-Börger E, Dura P, Nagengast FM, Epping LSM, Bisseling TM, Nagtegaal ID.

Eur J Gastroenterol Hepatol. 2019 Mar;31(3):340-344. doi: 10.1097/MEG.0000000000001328.

PMID:
30520764
3.

Features of incident colorectal cancer in Lynch syndrome.

Argillander TE, Koornstra JJ, van Kouwen M, Langers AM, Nagengast FM, Vecht J, de Vos Tot Nederveen Cappel WH, Dekker E, van Duijvendijk P, Vasen HF.

United European Gastroenterol J. 2018 Oct;6(8):1215-1222. doi: 10.1177/2050640618783554. Epub 2018 Jun 11.

4.

No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies.

Engel C, Vasen HF, Seppälä T, Aretz S, Bigirwamungu-Bargeman M, de Boer SY, Bucksch K, Büttner R, Holinski-Feder E, Holzapfel S, Hüneburg R, Jacobs MAJM, Järvinen H, Kloor M, von Knebel Doeberitz M, Koornstra JJ, van Kouwen M, Langers AM, van de Meeberg PC, Morak M, Möslein G, Nagengast FM, Pylvänäinen K, Rahner N, Renkonen-Sinisalo L, Sanduleanu S, Schackert HK, Schmiegel W, Schulmann K, Steinke-Lange V, Strassburg CP, Vecht J, Verhulst ML, de Vos Tot Nederveen Cappel W, Zachariae S, Mecklin JP, Loeffler M; German HNPCC Consortium, the Dutch Lynch Syndrome Collaborative Group, and the Finnish Lynch Syndrome Registry.

Gastroenterology. 2018 Nov;155(5):1400-1409.e2. doi: 10.1053/j.gastro.2018.07.030. Epub 2018 Jul 29.

PMID:
30063918
5.

Inflammatory potential of the diet and colorectal tumor risk in persons with Lynch syndrome.

Brouwer JG, Makama M, van Woudenbergh GJ, Vasen HF, Nagengast FM, Kleibeuker JH, Kampman E, van Duijnhoven FJ.

Am J Clin Nutr. 2017 Nov;106(5):1287-1294. doi: 10.3945/ajcn.117.152900. Epub 2017 Sep 20.

PMID:
28931533
6.

Incidence of small bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy.

Haanstra JF, Al-Toma A, Dekker E, Vanhoutvin SALW, Nagengast FM, Mathus-Vliegen EM, van Leerdam ME, de Vos Tot Nederveen Cappel WH, Veenendaal RA, Cats A, Sanduleanu S, Vasen HFA, Kleibeuker JH, Koornstra JJ.

Endosc Int Open. 2017 Jul;5(7):E622-E626. doi: 10.1055/s-0043-111723. Epub 2017 Jul 6.

7.

Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis.

Ghorbanoghli Z, Bastiaansen BA, Langers AM, Nagengast FM, Poley JW, Hardwick JC, Koornstra JJ, Sanduleanu S, de Vos Tot Nederveen Cappel WH, Witteman BJ, Morreau H, Dekker E, Vasen HF.

J Med Genet. 2018 Jan;55(1):11-14. doi: 10.1136/jmedgenet-2017-104545. Epub 2017 May 10.

PMID:
28490611
8.

Colorectal Cancer Risk in Patients With Lynch Syndrome and Inflammatory Bowel Disease.

Derikx LA, Smits LJ, van Vliet S, Dekker E, Aalfs CM, van Kouwen MC, Nagengast FM, Nagtegaal ID, Hoogerbrugge N, Hoentjen F.

Clin Gastroenterol Hepatol. 2017 Mar;15(3):454-458.e1. doi: 10.1016/j.cgh.2016.08.005. Epub 2016 Aug 10.

PMID:
27521512
9.

Hereditary cancer registries improve the care of patients with a genetic predisposition to cancer: contributions from the Dutch Lynch syndrome registry.

Vasen HF, Velthuizen ME, Kleibeuker JH, Menko FH, Nagengast FM, Cats A, van der Meulen-de Jong AE, Breuning MH, Roukema AJ, van Leeuwen-Cornelisse I, de Vos Tot Nederveen Cappel WH, Wijnen JT.

Fam Cancer. 2016 Jul;15(3):429-35. doi: 10.1007/s10689-016-9897-1.

10.

Randomized Comparison of Surveillance Intervals in Familial Colorectal Cancer.

Hennink SD, van der Meulen-de Jong AE, Wolterbeek R, Crobach AS, Becx MC, Crobach WF, van Haastert M, Ten Hove WR, Kleibeuker JH, Meijssen MA, Nagengast FM, Rijk MC, Salemans JM, Stronkhorst A, Tuynman HA, Vecht J, Verhulst ML, de Vos Tot Nederveen Cappel WH, Walinga H, Weinhardt OK, Westerveld D, Witte AM, Wolters HJ, Cats A, Veenendaal RA, Morreau H, Vasen HF.

J Clin Oncol. 2015 Dec 10;33(35):4188-93. doi: 10.1200/JCO.2015.62.2035. Epub 2015 Nov 2.

PMID:
26527788
11.

Low prevalence of serrated polyposis syndrome in screening populations: a systematic review.

van Herwaarden YJ, Verstegen MH, Dura P, Kievit W, Drenth JP, Dekker E, IJspeert JE, Hoogerbrugge N, Nagengast FM, Nagtegaal ID, Bisseling TM.

Endoscopy. 2015 Nov;47(11):1043-9. doi: 10.1055/s-0034-1392411. Epub 2015 Jun 30. Review.

PMID:
26126164
12.

A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer.

Weren RD, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, Spruijt L, van Zelst-Stams WA, Jongmans MC, Gilissen C, Hehir-Kwa JY, Hoischen A, Shendure J, Boyle EA, Kamping EJ, Nagtegaal ID, Tops BB, Nagengast FM, Geurts van Kessel A, van Krieken JH, Kuiper RP, Hoogerbrugge N.

Nat Genet. 2015 Jun;47(6):668-71. doi: 10.1038/ng.3287. Epub 2015 May 4.

PMID:
25938944
13.

Prevalence of small-bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy.

Haanstra JF, Al-Toma A, Dekker E, Vanhoutvin SA, Nagengast FM, Mathus-Vliegen EM, van Leerdam ME, de Vos tot Nederveen Cappel WH, Sanduleanu S, Veenendaal RA, Cats A, Vasen HF, Kleibeuker JH, Koornstra JJ.

Gut. 2015 Oct;64(10):1578-83. doi: 10.1136/gutjnl-2014-307348. Epub 2014 Sep 10.

PMID:
25209657
14.

Dietary B vitamin and methionine intake and MTHFR C677T genotype on risk of colorectal tumors in Lynch syndrome: the GEOLynch cohort study.

Jung AY, van Duijnhoven FJ, Nagengast FM, Botma A, Heine-Bröring RC, Kleibeuker JH, Vasen HF, Harryvan JL, Winkels RM, Kampman E.

Cancer Causes Control. 2014 Sep;25(9):1119-29. doi: 10.1007/s10552-014-0412-4. Epub 2014 Jun 12.

PMID:
24916333
15.

Over-expression of COX-2 mRNA in colorectal cancer.

Roelofs HM, Te Morsche RH, van Heumen BW, Nagengast FM, Peters WH.

BMC Gastroenterol. 2014 Jan 2;14:1. doi: 10.1186/1471-230X-14-1.

16.

Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls.

van Heumen BW, Roelofs HM, te Morsche RH, Nagengast FM, Peters WH.

Orphanet J Rare Dis. 2013 Nov 19;8:181. doi: 10.1186/1750-1172-8-181.

17.

Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.

van Heumen BW, Roelofs HM, Vink-Börger ME, Dekker E, Mathus-Vliegen EM, Dees J, Koornstra JJ, Langers AM, Nagtegaal ID, Kampman E, Peters WH, Nagengast FM.

Orphanet J Rare Dis. 2013 Aug 6;8:118. doi: 10.1186/1750-1172-8-118.

18.

Dietary Supplement Use and Colorectal Adenoma Risk in Individuals with Lynch Syndrome: The GEOLynch Cohort Study.

Heine-Bröring RC, Winkels RM, Botma A, van Duijnhoven FJ, Jung AY, Kleibeuker JH, Nagengast FM, Vasen HF, Kampman E.

PLoS One. 2013 Jun 18;8(6):e66819. doi: 10.1371/journal.pone.0066819. Print 2013.

19.

Do lifestyle factors influence colorectal cancer risk in Lynch syndrome?

van Duijnhoven FJ, Botma A, Winkels R, Nagengast FM, Vasen HF, Kampman E.

Fam Cancer. 2013 Jun;12(2):285-93. doi: 10.1007/s10689-013-9645-8. Review.

PMID:
23657759
20.

Extracolonic cancer risk in patients with serrated polyposis syndrome and their first-degree relatives.

Hazewinkel Y, Reitsma JB, Nagengast FM, Vasen HF, van Os TA, van Leerdam ME, Koornstra JJ, Dekker E.

Fam Cancer. 2013 Dec;12(4):669-73. doi: 10.1007/s10689-013-9643-x.

PMID:
23591707
21.

Familial colorectal cancer risk assessment needs improvement for more effective cancer prevention in relatives.

Dekker N, Hermens RP, Nagengast FM, van Zelst-Stams WA, Hoogerbrugge N; RISCO study group.

Colorectal Dis. 2013 Apr;15(4):e175-85; discussion p.e185. doi: 10.1111/codi.12117.

PMID:
23451840
22.

Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts.

Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Møller P, Myrhoj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJ, Rahner N, Wijnen JT, Järvinen HJ, Möslein G; Mallorca group.

Gut. 2013 Jun;62(6):812-23. doi: 10.1136/gutjnl-2012-304356. Epub 2013 Feb 13.

23.

Dietary patterns and colorectal adenomas in Lynch syndrome: the GEOLynch cohort study.

Botma A, Vasen HF, van Duijnhoven FJ, Kleibeuker JH, Nagengast FM, Kampman E.

Cancer. 2013 Feb 1;119(3):512-21. doi: 10.1002/cncr.27726. Epub 2012 Dec 17. Erratum in: Cancer. 2013 Jun 15;119(12):2358.

24.

The influence of curcumin, quercetin, and eicosapentaenoic acid on the expression of phase II detoxification enzymes in the intestinal cell lines HT-29, Caco-2, HuTu 80, and LT97.

Odenthal J, van Heumen BW, Roelofs HM, te Morsche RH, Marian B, Nagengast FM, Peters WH.

Nutr Cancer. 2012 Aug;64(6):856-63. doi: 10.1080/01635581.2012.700994. Epub 2012 Jul 25.

PMID:
22830632
25.

Dietary supplement use is not associated with recurrence of colorectal adenomas: a prospective cohort study.

Heine-Bröring RC, Winkels RM, Botma A, Wahab PJ, Tan AC, Nagengast FM, Witteman BJ, Kampman E.

Int J Cancer. 2013 Feb 1;132(3):666-75. doi: 10.1002/ijc.27647. Epub 2012 Jun 20.

26.

Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy.

Haanstra JF, de Vos Tot Nederveen Cappel WH, Gopie JP, Vecht J, Vanhoutvin SA, Cats A, van der Zaag-Loonen HJ, Langers AM, Bergmann JH, van de Meeberg PC, Dekker E, Kleibeuker JH, Vasen HF, Nagengast FM, van Duijvendijk P.

Dis Colon Rectum. 2012 Jun;55(6):653-9. doi: 10.1097/DCR.0b013e31824f5392.

PMID:
22595844
27.

Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.

van Heumen BW, Roelofs HM, Te Morsche RH, Marian B, Nagengast FM, Peters WH.

Exp Cell Res. 2012 Apr 15;318(7):819-27. doi: 10.1016/j.yexcr.2012.02.004. Epub 2012 Feb 14.

PMID:
22366264
28.

A prospective study of bowel preparation for colonoscopy with polyethylene glycol-electrolyte solution versus sodium phosphate in Lynch syndrome: a randomized trial.

van Vugt van Pinxteren MW, van Kouwen MC, van Oijen MG, van Achterberg T, Nagengast FM.

Fam Cancer. 2012 Sep;11(3):337-41. doi: 10.1007/s10689-012-9517-7.

29.

Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologist's initiative.

Landsbergen KM, Prins JB, Brunner HG, van Duijvendijk P, Nagengast FM, van Krieken JH, Ligtenberg M, Hoogerbrugge N.

Fam Cancer. 2012 Jun;11(2):259-67. doi: 10.1007/s10689-012-9510-1.

30.

Surgical management for advanced duodenal adenomatosis and duodenal cancer in Dutch patients with familial adenomatous polyposis: a nationwide retrospective cohort study.

van Heumen BW, Nieuwenhuis MH, van Goor H, Mathus-Vliegen LE, Dekker E, Gouma DJ, Dees J, van Eijck CH, Vasen HF, Nagengast FM.

Surgery. 2012 May;151(5):681-90. doi: 10.1016/j.surg.2011.12.008. Epub 2012 Jan 21.

PMID:
22265391
31.

Management of sporadic duodenal adenomas and the association with colorectal neoplasms: a retrospective cohort study.

van Heumen BW, Mul K, Nagtegaal ID, van Kouwen MC, Nagengast FM.

J Clin Gastroenterol. 2012 May-Jun;46(5):390-6. doi: 10.1097/MCG.0b013e318238e72d.

PMID:
22178960
32.

Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome.

Winkels RM, Botma A, Van Duijnhoven FJ, Nagengast FM, Kleibeuker JH, Vasen HF, Kampman E.

Gastroenterology. 2012 Feb;142(2):241-7. doi: 10.1053/j.gastro.2011.10.033. Epub 2011 Nov 4.

PMID:
22062356
33.

High prevalence of fatigue in inflammatory bowel disease: A case control study.

Römkens TE, van Vugt-van Pinxteren MW, Nagengast FM, van Oijen MG, de Jong DJ.

J Crohns Colitis. 2011 Aug;5(4):332-7. doi: 10.1016/j.crohns.2011.02.008. Epub 2011 Mar 24.

PMID:
21683303
34.

Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis.

Friederich P, Verschuur J, van Heumen BW, Roelofs HM, Berkhout M, Nagtegaal ID, van Oijen MG, van Krieken JH, Peters WH, Nagengast FM.

Int J Colorectal Dis. 2011 May;26(5):575-82. doi: 10.1007/s00384-010-1127-y. Epub 2011 Jan 18.

35.

Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients.

Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG, Nagengast FM, van der Bijl J, van Dalsen AD, Kleibeuker JH, Dekker E, Langers AM, Vecht J, Peters FT, van Dam R, van Gemert WG, Stuifbergen WN, Schouten WR, Gelderblom H, Vasen HF.

Br J Cancer. 2011 Jan 4;104(1):37-42. doi: 10.1038/sj.bjc.6605997. Epub 2010 Nov 9.

36.

High detection rate of adenomas in familial colorectal cancer.

van der Meulen-de Jong AE, Morreau H, Becx MC, Crobach LF, van Haastert M, ten Hove WR, Kleibeuker JH, Meijssen MA, Nagengast FM, Rijk MC, Salemans JM, Stronkhorst A, Tuynman HA, Vecht J, Verhulst ML, de Vos tot Nederveen Cappel WH, Walinga H, Weinhardt OK, Westerveld BD, Witte AM, Wolters HJ, Vasen HF.

Gut. 2011 Jan;60(1):73-6. doi: 10.1136/gut.2010.217091. Epub 2010 Sep 9.

PMID:
20833659
37.

Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study.

Botma A, Nagengast FM, Braem MG, Hendriks JC, Kleibeuker JH, Vasen HF, Kampman E.

J Clin Oncol. 2010 Oct 1;28(28):4346-53. doi: 10.1200/JCO.2010.28.0453. Epub 2010 Aug 23.

PMID:
20733131
38.

Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome.

Boparai KS, Reitsma JB, Lemmens V, van Os TA, Mathus-Vliegen EM, Koornstra JJ, Nagengast FM, van Hest LP, Keller JJ, Dekker E.

Gut. 2010 Sep;59(9):1222-5. doi: 10.1136/gut.2009.200741. Epub 2010 Jun 28.

PMID:
20584785
39.

Peutz-Jeghers syndrome: a systematic review and recommendations for management.

Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Friedl W, Møller P, Hes FJ, Järvinen H, Mecklin JP, Nagengast FM, Parc Y, Phillips RK, Hyer W, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen JT, Clark SK, Hodgson SV.

Gut. 2010 Jul;59(7):975-86. doi: 10.1136/gut.2009.198499.

PMID:
20581245
40.

Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial.

Overbeek LI, Hermens RP, van Krieken JH, Adang EM, Casparie M, Nagengast FM, Ligtenberg MJ, Hoogerbrugge N; MIPA study group.

Virchows Arch. 2010 Jun;456(6):653-9. doi: 10.1007/s00428-010-0907-7. Epub 2010 Apr 9.

41.

One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.

Vasen HF, Abdirahman M, Brohet R, Langers AM, Kleibeuker JH, van Kouwen M, Koornstra JJ, Boot H, Cats A, Dekker E, Sanduleanu S, Poley JW, Hardwick JC, de Vos Tot Nederveen Cappel WH, van der Meulen-de Jong AE, Tan TG, Jacobs MA, Mohamed FL, de Boer SY, van de Meeberg PC, Verhulst ML, Salemans JM, van Bentem N, Westerveld BD, Vecht J, Nagengast FM.

Gastroenterology. 2010 Jun;138(7):2300-6. doi: 10.1053/j.gastro.2010.02.053. Epub 2010 Mar 2.

PMID:
20206180
42.

Improving calculation, interpretation and communication of familial colorectal cancer risk: protocol for a randomized controlled trial.

Dekker N, Hermens RP, Elwyn G, van der Weijden T, Nagengast FM, van Duijvendijk P, Salemink S, Adang E, van Krieken JH, Ligtenberg MJ, Hoogerbrugge N.

Implement Sci. 2010 Jan 28;5:6. doi: 10.1186/1748-5908-5-6.

43.

Increased consumption of fatty and lean fish reduces serum C-reactive protein concentrations but not inflammation markers in feces and in colonic biopsies.

Pot GK, Geelen A, Majsak-Newman G, Harvey LJ, Nagengast FM, Witteman BJ, van de Meeberg PC, Hart AR, Schaafsma G, Lund EK, Rijkers GT, Kampman E.

J Nutr. 2010 Feb;140(2):371-6. doi: 10.3945/jn.109.113472. Epub 2009 Dec 23.

PMID:
20032491
44.

Increasing fish consumption does not affect genotoxicity markers in the colon in an intervention study.

Pot GK, Habermann N, Majsak-Newman G, Harvey LJ, Geelen A, Przybylska-Philips K, Nagengast FM, Witteman BJ, van de Meeberg PC, Hart AR, Schaafsma G, Hooiveld G, Glei M, Lund EK, Pool-Zobel BL, Kampman E.

Carcinogenesis. 2010 Jun;31(6):1087-91. doi: 10.1093/carcin/bgp255. Epub 2009 Oct 27.

PMID:
19861650
45.

In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response.

Meijer TW, Hoogerbrugge N, Nagengast FM, Ligtenberg MJ, van Krieken JH.

Histopathology. 2009 Oct;55(4):414-22. doi: 10.1111/j.1365-2559.2009.03403.x.

PMID:
19817892
46.

COX-2 polymorphisms -765G-->C and -1195A-->G and colorectal cancer risk.

Hoff JH, te Morsche RH, Roelofs HM, van der Logt EM, Nagengast FM, Peters WH.

World J Gastroenterol. 2009 Sep 28;15(36):4561-5.

47.

Recommendations to improve identification of hereditary and familial colorectal cancer in Europe.

Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bulow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Rahner N, Hes FJ, Hodgson S, Mecklin JP, Møller P, Myrhøj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen J, Lubinski J, Järvinen H, Claes E, Heinimann K, Karagiannis JA, Lindblom A, Dove-Edwin I, Müller H.

Fam Cancer. 2010 Jun;9(2):109-15. doi: 10.1007/s10689-009-9291-3. Epub 2009 Sep 18.

PMID:
19763885
48.

Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study.

Boparai KS, Mathus-Vliegen EM, Koornstra JJ, Nagengast FM, van Leerdam M, van Noesel CJ, Houben M, Cats A, van Hest LP, Fockens P, Dekker E.

Gut. 2010 Aug;59(8):1094-100. doi: 10.1136/gut.2009.185884. Epub 2009 Aug 25.

PMID:
19710031
49.

Fish consumption and markers of colorectal cancer risk: a multicenter randomized controlled trial.

Pot GK, Majsak-Newman G, Geelen A, Harvey LJ, Nagengast FM, Witteman BJ, van de Meeberg PC, Timmer R, Tan A, Wahab PJ, Hart AR, Williams MP, Przybylska-Phillips K, Dainty JR, Schaafsma G, Kampman E, Lund EK; FISHGASTRO Study Group.

Am J Clin Nutr. 2009 Aug;90(2):354-61. doi: 10.3945/ajcn.2009.27630. Epub 2009 Jun 24.

PMID:
19553301
50.

COX-2 polymorphisms in patients with familial adenomatous polyposis.

Peters WH, te Morsche RH, Roelofs HM, Mathus-Vliegen EM, Berkhout M, Nagengast FM.

Oncol Res. 2009;17(8):347-51.

PMID:
19544971

Supplemental Content

Loading ...
Support Center